Ceftolozane/Tazobactam is a combination of two medications used to treat bacterial infections. Ceftolozane is an antibiotic that works by killing bacteria or stopping their growth. Tazobactam is a substance that helps ceftolozane work better by preventing bacteria from breaking it down. In this clinical trial, the combination is being tested to see if it is safe and well-tolerated in children with a type of lung infection called nosocomial pneumonia, which is an infection acquired in a hospital setting.

Nosocomial infection – Nosocomial infections, also known as hospital-acquired infections, occur in patients during their stay in a healthcare facility. These infections are not present or incubating at the time of admission. They can be caused by bacteria, viruses, or fungi, often due to invasive procedures or weakened immune systems. The progression of nosocomial infections can vary depending on the pathogen and the patient’s health. Symptoms may include fever, inflammation, and other site-specific signs. These infections can spread within the healthcare setting if not properly controlled.

Pneumonia – Pneumonia is an infection that inflames the air sacs in one or both lungs, which may fill with fluid or pus. It can be caused by bacteria, viruses, or fungi. The disease often begins with symptoms similar to a cold or flu, such as cough, fever, and difficulty breathing. As it progresses, symptoms can become more severe, including chest pain and a persistent cough with phlegm. Pneumonia can affect people of all ages but is more serious in infants, older adults, and those with weakened immune systems. The progression and severity depend on the cause and the individual’s overall health.